Medicines not recommended for inclusion in the who essential medicines list: a retrospective observational study
An appreciable proportion of applications for addition of new medicines to the EML are not recommended. Over time, low or limited quality of clinical evidence was a consistent explanatory reason leading to non-recommending. Economic considerations and feasibility are emerging justifications for non-recommending.
Authors
- Hendrika A. van den Ham (ORCID: https://orcid.org/0000-0003-1339-9818)
- Enrico Costa (ORCID: https://orcid.org/0000-0003-2616-994X)
- Armando A. Genazzani (ORCID: https://orcid.org/0000-0003-1923-7430)
- Veronika J. Wirtz (ORCID: https://orcid.org/0000-0002-0863-8768)
- Lorenzo Moja (ORCID: https://orcid.org/0000-0001-6680-6507)
- Hubert G. M. Leufkens (ORCID: https://orcid.org/0000-0002-7175-1499)
- Benedikt Huttner (ORCID: https://orcid.org/0000-0002-1749-9464)
- Francesco Nonino (ORCID: https://orcid.org/0000-0003-3601-6381)
- Nicola Magrini (ORCID: https://orcid.org/0000-0002-0657-5716)
- Bernadette Cappello
- Vittorio Del Grosso
Institutions
- Boston University (US)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Utrecht University (NL)
- World Health Organization (CH)
- Evidence (Italy) (IT)
- University of Turin (IT)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-03-17
- DOI
- https://doi.org/10.3389/fmed.2025.1517020
- Citations
- 2
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 6.99